Login
$CMPS
$8.35 +$0.08 (0.95%) After hours

$CMPS 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Results of Operations and Financial Condition

LONDON & JERSEY CITY--(November 3, 2026) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial ...

05 Aug 2026 8-K: Results of Operations and Financial Condition

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlig...

07 Jul 2026 8-K: Regulation FD Disclosure; Other Events

© Compass Pathways | 1 Compass Pathways Phase 3 COMP006 data review July 7, 2026

28 May 2026 8-K: Submission of Matters to a Vote of Security Holders

(a) On May 27, 2026, COMPASS Pathways plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). Of the ordinary shares entitled to vote, there were 58,880,058 ordinary shares represented in person or by proxy ...

13 May 2026 8-K: Results of Operations and Financial Condition

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights.

24 Mar 2026 8-K: Results of Operations and Financial Condition

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business high...

19 Feb 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

1.INTRODUCTORY. COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales with registered number 12696098 (the “Company”), proposes to sell, pursuant to the terms of this Agreement (the “Agreement”),...

17 Feb 2026 8-K: Regulation FD Disclosure; Other Events

1 | © Compass Pathways COMP360 Phase 3 Program Topline Results COMP005 & COMP006 February 17, 2026

07 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

Certain confidential information in this document has been omitted from this exhibit and replaced with “[***]” because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

04 Nov 2025 8-K: Results of Operations and Financial Condition

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

29 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

LONDON & NEW YORK--(October 29, 2025)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey J...

31 Jul 2025 8-K: Results of Operations and Financial Condition

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2025 and provided an update ...

29 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Justin Gover to its Board of Directors, effective imm...

23 Jun 2025 8-K: Other Events

Compass Pathways plc (the “Company”) announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psi...

13 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

(a) On June 12, 2025, COMPASS Pathways plc (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “AGM”). Of the ordinary shares entitled to vote, there were 62,355,281 ordinary shares represented in person or by proxy...

08 May 2025 8-K: Results of Operations and Financial Condition

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update o...

16 Apr 2025 8-K: Changes in Registrant's Certifying Accountant; Departure/Election of Directors or Officers; Compensation

We have read the statements made by Compass Pathways plc (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Compass Pathways plc dated April 16, 2025. We a...

27 Feb 2025 8-K: Results of Operations and Financial Condition

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2024 and provi...

10 Jan 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

1.INTRODUCTORY. COMPASS Pathways plc, a public limited company incorporated under the laws of England and Wales with registered number 12696098 (the “Company”), proposes to sell, pursuant to the terms of this Agreement (the “Agreement”),...

31 Oct 2024 8-K: Results of Operations and Financial Condition

Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on rec...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support